About Teduglutide
GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility
Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel. A systematic review and meta-analysis of Phase 3 registrational trial data published in the Journal of Parenteral and Enteral Nutrition documented significant reductions in parenteral nutrition volume requirements, and long-term follow-up data published in Clinical and Translational Gastroenterology confirmed durable reductions in parenteral support needs over extended treatment periods. Teduglutide is an FDA-approved prescription medication; it is indicated for adults and pediatric patients (≥1 year) with SBS dependent on parenteral support, and use outside this indication or without physician supervision is not supported by established safety and efficacy data.
Teduglutide Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- December 21, 2012
- Source
- View FDA source →
FDA-approved GLP-2 analog. Brand: Gattex (NDA 203441, Dec 2012). Indicated for short bowel syndrome in adults and paediatric patients. Daily subcutaneous injection. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
7 sources cited · 7 moderate
1 RCT · 4 Cohorts · 2 Reviews
From childhood to adulthood in chronic intestinal failure: A nationwide study.
Clin Nutr · 2026
# Summary This nationwide study demonstrated that teduglutide was the only therapeutic factor associated with reduced dependence on home parenteral nutrition in adults who had childhood-onset chronic intestinal failure. Research found that while survival rates remained high (91%) in this patient population, persistent parenteral nutrition dependence (95%) was common, suggesting that GLP-2 analogues like teduglutide may offer a meaningful therapeutic avenue for improving long-term outcomes.
A Long-Acting Glucagon-like Peptide 2 Protracted by Coomassie Brilliant Blue to Enhance Intestinal Growth in Mice.
Bioconjug Chem · 2026
# Summary Research found that a modified version of teduglutide created by conjugating Coomassie brilliant blue demonstrated significantly extended circulation time in the body while maintaining therapeutic potency and producing enhanced intestinal growth in mice. This study demonstrated that the modified compound achieved greater intestinal tissue development compared to standard teduglutide, suggesting potential for reducing injection frequency in treatment approaches.
Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.
Clin Nutr ESPEN · 2026
Research found that in real-world clinical practice, patients with short bowel syndrome-associated intestinal failure experienced reductions in parenteral nutrition and intravenous fluid dependence whether or not they received teduglutide treatment, with similar overall reductions in PN/IV frequency and volume observed in both groups over approximately 19 months of follow-up. This study demonstrated that while teduglutide-treated patients showed slightly higher reductions in energy received from PN/IV support, the differences between treated and untreated cohorts were modest, suggesting variable treatment responses in clinical practice settings.
Show 4 more sources ↓
PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.
JPGN Rep · 2026
# Summary Research found that teduglutide enabled a child with a novel PERCC1 gene mutation causing severe congenital enteropathy to achieve independence from parenteral nutrition after two years of dependency. This study demonstrated that teduglutide may represent a therapeutic option for reducing nutritional support requirements in certain genetic forms of congenital diarrhea and enteropathy.
Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?
Curr Opin Gastroenterol · 2026
# Summary Research found that GLP-2 agonists, particularly teduglutide, demonstrate improvements in intestinal absorption and reduce the need for parenteral support in short bowel syndrome patients while maintaining favorable safety profiles. This study identified emerging longer-acting agents as promising alternatives with less frequent dosing requirements and noted that GLP-1 agonists may offer complementary benefits for future treatment strategies.
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
Clinical and Translational Gastroenterology · 2016
Research in the STEPS-2 open-label extension study found that up to 30 months of teduglutide reduced mean weekly parenteral support volume by 66% in patients who received teduglutide throughout, with 13 patients achieving complete enteral autonomy and stable nutritional status maintained despite substantial parenteral nutrition reductions.
Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review
Journal of Parenteral and Enteral Nutrition · 2015
This systematic review of phase 3 randomized controlled trials and extension studies found that teduglutide (a GLP-2 analog) consistently reduced parenteral nutrition requirements compared with placebo in adults with intestinal failure, with an adverse event profile comparable to placebo, supporting its role in promoting intestinal adaptation and reducing long-term parenteral dependence.
Teduglutide Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Teduglutide — Providers & Availability
Coverage expanding
No verified providers currently list Teduglutide. Get notified when one does, or explore providers carrying similar peptides in the Recovery category.
Stay updated on verified Teduglutide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Teduglutide
Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel.
intestinal growth, gut repair, absorptive surface restoration, short bowel syndrome treatment.
Research on Teduglutide primarily documents effects related to intestinal growth and gut repair and absorptive surface restoration and short bowel syndrome treatment. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Teduglutide include GI malignancy or history, colorectal polyps (monitor). This is educational information only — consult a qualified healthcare professional before use.
# Summary This nationwide study demonstrated that teduglutide was the only therapeutic factor associated with reduced dependence on home parenteral nutrition in adults who had childhood-onset chronic intestinal failure. Research found that while survival rates remained high (91%) in this patient population, persistent parenteral nutrition dependence (95%) was common, suggesting that GLP-2 analogues like teduglutide may offer a meaningful therapeutic avenue for improving long-term outcomes.